{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T01:40:35Z","timestamp":1772242835509,"version":"3.50.1"},"reference-count":46,"publisher":"Informa UK Limited","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ocular Immunology and Inflammation"],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.3109\/09273948.2013.779727","type":"journal-article","created":{"date-parts":[[2013,6,4]],"date-time":"2013-06-04T10:54:42Z","timestamp":1370343282000},"page":"468-474","source":"Crossref","is-referenced-by-count":47,"title":["Long-term Clinical Outcomes in Patients with Refractory Uveitis Associated with Beh\u00e7et Disease Treated with Infliximab"],"prefix":"10.1080","volume":"21","author":[{"given":"Sultan","family":"Al Rashidi","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, College of Medicine, King Saud University","place":["Saudi Arabia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdullah","family":"Al Fawaz","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, College of Medicine, King Saud University","place":["Saudi Arabia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dustan","family":"Kangave","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, College of Medicine, King Saud University","place":["Saudi Arabia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed M.","family":"Abu El-Asrar","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, College of Medicine, King Saud University","place":["Saudi Arabia"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2013,6,4]]},"reference":[{"key":"e_1_3_2_2_1","first-page":"1078","article-title":"Criteria for diagnosis of Beh\u00e7et's disease","volume":"335","author":"International Study Group for Beh\u00e7et's Disease","year":"1990","unstructured":"International Study Group for Beh\u00e7et's Disease. Criteria for diagnosis of Beh\u00e7et's disease. Lancet. 1990;335:1078\u20131080","journal-title":"Lancet."},{"key":"e_1_3_2_3_1","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.9.9.1993"},{"key":"e_1_3_2_4_1","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.ajo.2004.03.022","article-title":"Uveitis in Beh\u00e7et's disease: an analysis of 880 patients","volume":"138","author":"Tugal-Tukun I","year":"2004","unstructured":"Tugal-Tukun I, Onal S, Altan-Yaycioglu R, et al. Uveitis in Beh\u00e7et's disease: an analysis of 880 patients. Am J Ophthalmol. 2004;138:373\u2013380","journal-title":"Am J Ophthalmol."},{"key":"e_1_3_2_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2011.01.014"},{"key":"e_1_3_2_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.imbio.2011.03.007"},{"key":"e_1_3_2_7_1","first-page":"1544","article-title":"Overproduction of monocyte derived tumor necrosis factor alpha, interleukin (IL) 6, IL-8 and increased neutrophil superoxide generation in Beh\u00e7et's disease: a comparative study with familial Mediterranean fever and healthy subjects","volume":"20","author":"Mage JL","year":"1993","unstructured":"Mage JL, Dilsen N, Sanguedolce V, et al. Overproduction of monocyte derived tumor necrosis factor alpha, interleukin (IL) 6, IL-8 and increased neutrophil superoxide generation in Beh\u00e7et's disease: a comparative study with familial Mediterranean fever and healthy subjects. J Rheumatol. 1993;20:1544\u20131549","journal-title":"J Rheumatol."},{"key":"e_1_3_2_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2003.09.003"},{"key":"e_1_3_2_9_1","first-page":"128","article-title":"Systemic levels of the T cell regulatory cytokines IL-10 and IL-12 in Beh\u00e7et's disease: soluble TNFR-75 as a biological marker of disease activity","volume":"24","author":"Turan B","year":"1997","unstructured":"Turan B, Gallati H, Erdi H, et al. Systemic levels of the T cell regulatory cytokines IL-10 and IL-12 in Beh\u00e7et's disease: soluble TNFR-75 as a biological marker of disease activity. J Rheumatol. 1997;24:128\u2013132","journal-title":"J Rheumatol."},{"key":"e_1_3_2_10_1","doi-asserted-by":"publisher","DOI":"10.1080\/09629350220131935"},{"key":"e_1_3_2_11_1","doi-asserted-by":"publisher","DOI":"10.1076\/ocii.12.1.53.28062"},{"key":"e_1_3_2_12_1","doi-asserted-by":"publisher","DOI":"10.1159\/000055677"},{"key":"e_1_3_2_13_1","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.03-0659"},{"key":"e_1_3_2_14_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-140-5-200403020-00025"},{"key":"e_1_3_2_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.21231"},{"key":"e_1_3_2_16_1","first-page":"1362","article-title":"Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Beh\u00e7et's disease with refractory uveoretinitis","volume":"31","author":"Ohno S","year":"2004","unstructured":"Ohno S, Makamura S, Hori S, et al. Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Beh\u00e7et's disease with refractory uveoretinitis. J Rheumatol. 2004;31:1362\u20131368","journal-title":"J Rheumatol."},{"key":"e_1_3_2_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0755-4982(05)84079-5"},{"key":"e_1_3_2_18_1","first-page":"S14","article-title":"Infliximab in refractory uveitis due to Beh\u00e7et's disease","volume":"22","author":"Wechsler B","year":"2004","unstructured":"Wechsler B, Sable-Fourtassou R, Bodaghi B, et al. Infliximab in refractory uveitis due to Beh\u00e7et's disease. Clin Exp Rheumatol. 2004;22:S14\u2013S16","journal-title":"Clin Exp Rheumatol."},{"key":"e_1_3_2_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10792-006-9006-9"},{"key":"e_1_3_2_20_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kem101"},{"key":"e_1_3_2_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-008-0606-8"},{"key":"e_1_3_2_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10384-006-0425-y"},{"key":"e_1_3_2_23_1","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.2010.194464"},{"key":"e_1_3_2_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2008.09.010"},{"key":"e_1_3_2_25_1","doi-asserted-by":"publisher","DOI":"10.1196\/annals.1423.050"},{"key":"e_1_3_2_26_1","doi-asserted-by":"publisher","DOI":"10.3109\/09273948.2012.665124"},{"key":"e_1_3_2_27_1","doi-asserted-by":"publisher","DOI":"10.3109\/09273948.2012.670360"},{"key":"e_1_3_2_28_1","doi-asserted-by":"publisher","DOI":"10.1001\/archophthalmol.2011.2698"},{"key":"e_1_3_2_29_1","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.2009.168856"},{"key":"e_1_3_2_30_1","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.2009.174888"},{"key":"e_1_3_2_31_1","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.10-5916"},{"key":"e_1_3_2_32_1","doi-asserted-by":"publisher","DOI":"10.1177\/112067210201200514"},{"key":"e_1_3_2_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2004.04.066"},{"key":"e_1_3_2_34_1","doi-asserted-by":"publisher","DOI":"10.1089\/jop.2009.0054"},{"key":"e_1_3_2_35_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10384-010-0824-y"},{"key":"e_1_3_2_36_1","doi-asserted-by":"publisher","DOI":"10.1159\/000329190"},{"key":"e_1_3_2_37_1","first-page":"S65","article-title":"Infliximab treatment-induced formation of autoantibodies is common in Beh\u00e7et's disease","volume":"25","author":"Elezoglou A","year":"2007","unstructured":"Elezoglou A, Kafasi N, Kaklamanis PH, et al. Infliximab treatment-induced formation of autoantibodies is common in Beh\u00e7et's disease. Clin Exp Rheumatol. 2007;25:S65\u2013S69","journal-title":"Clin Exp Rheumatol."},{"key":"e_1_3_2_38_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-011-1908-1"},{"key":"e_1_3_2_39_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10792-010-9372-1"},{"key":"e_1_3_2_40_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.20712"},{"key":"e_1_3_2_41_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.22718"},{"key":"e_1_3_2_42_1","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v13.i39.5238"},{"key":"e_1_3_2_43_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kes130"},{"key":"e_1_3_2_44_1","doi-asserted-by":"publisher","DOI":"10.3109\/09273948.2010.483314"},{"key":"e_1_3_2_45_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.eye.6702352"},{"key":"e_1_3_2_46_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-009-1178-y"},{"key":"e_1_3_2_47_1","first-page":"S54","article-title":"Efficacy of adalimumab in patients with Beh\u00e7et's disease unsuccessfully treated with infliximab","volume":"29","author":"Olivieri I","year":"2011","unstructured":"Olivieri I, Leccese P, D'Angelo S, et al. Efficacy of adalimumab in patients with Beh\u00e7et's disease unsuccessfully treated with infliximab. Clin Exp Rheumatol. 2011;29:S54\u2013S57","journal-title":"Clin Exp Rheumatol."}],"container-title":["Ocular Immunology and Inflammation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.3109\/09273948.2013.779727","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T21:27:02Z","timestamp":1770931622000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.3109\/09273948.2013.779727"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,6,4]]},"references-count":46,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["10.3109\/09273948.2013.779727"],"URL":"https:\/\/doi.org\/10.3109\/09273948.2013.779727","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.718017435.793494130","asserted-by":"object"}]},"ISSN":["0927-3948","1744-5078"],"issn-type":[{"value":"0927-3948","type":"print"},{"value":"1744-5078","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,6,4]]}}}